RCKT (Rocket Pharmaceuticals) General and Admin. Expense: $75.11 Mil (TTM As of Mar. 2026)


RCKT Rocket Pharmaceuticals Inc RCKT
30 GF Score
Price $3.84
! 3 Warning Signs
View Full Analysis

What is Rocket Pharmaceuticals General and Admin. Expense?

Rocket Pharmaceuticals RCKT +9.25% 30 General and Admin. Expense is $75.11 Mil as of Mar. 2026. GuruFocus rates RCKT with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Rocket Pharmaceuticals's General and Admin. Expense for the three months ended in Mar. 2026 was $17.06 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $75.11 Mil.

Rocket Pharmaceuticals General and Admin. Expense Related Terms

Rocket Pharmaceuticals General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Rocket Pharmaceuticals's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rocket Pharmaceuticals General and Admin. Expense Chart

Rocket Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.77 58.77 73.32 101.96 86.50

Rocket Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.45 25.02 18.35 14.68 17.06
RCKT
30GF Score
Rocket Pharmaceuticals Inc RCKT
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rocket Pharmaceuticals General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $75.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $75.11 Mil mean?
Rocket Pharmaceuticals (RCKT) has a General and Admin. Expense of $75.11 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Rocket Pharmaceuticals and its competitors.
Is Rocket Pharmaceuticals' General and Admin. Expense too high?
Rocket Pharmaceuticals' current General and Admin. Expense is $75.11 Mil. Overall, Rocket Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' General and Admin. Expense compare to TENX and DMAC?
Rocket Pharmaceuticals' General and Admin. Expense of $75.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Rocket Pharmaceuticals and its competitors. Rocket Pharmaceuticals's current General and Admin. Expense is $75.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (RCKT) has a current General and Admin. Expense of $75.11 Mil. The current General and Admin. Expense is $75.11 Mil. Rocket Pharmaceuticals' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Rocket Pharmaceuticals (RCKT), the current General and Admin. Expense is $75.11 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rocket Pharmaceuticals Business Description

Other Exchanges 9IP1:Germany
Address 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
30GF Score

Get the complete analysis for RCKT

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84
Price